S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
OTCMKTS:IPHYF

Innate Pharma (IPHYF) Stock Price, News & Analysis

$2.58
+0.24 (+10.26%)
(As of 03/28/2024 ET)
Today's Range
$2.39
$2.65
50-Day Range
$2.34
$2.84
52-Week Range
$2.30
$3.37
Volume
800 shs
Average Volume
280 shs
Market Capitalization
$206.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IPHYF stock logo

About Innate Pharma Stock (OTCMKTS:IPHYF)

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH4501, an antibody drug conjugates (ADC); and IPH65, a tetra-specific proprietary antibody. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

IPHYF Stock Price History

IPHYF Stock News Headlines

Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
Innate Pharma SA (IPHYF) Receives a Hold from Kepler Capital
Innate Pharma: Worth A Deeper Look
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Innate Pharma to Host Virtual KOL Event on Lacutamab
H.C. Wainwright Reaffirms Their Buy Rating on Innate Pharma (IPHA)
See More Headlines
Receive IPHYF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
OTCMKTS:IPHYF
Previous Symbol
NASDAQ:IPHYF
Employees
191
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$66.71 million
Book Value
$0.70 per share

Miscellaneous

Free Float
54,632,000
Market Cap
$206.94 million
Optionable
Not Optionable
Beta
1.14
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Herve Brailly Ph.D. (Age 63)
    Co-Founder, Interim CEO & Chairman of Executive Board
  • Mr. Yannis Morel Ph.D. (Age 51)
    Executive VP, COO & Member of Executive Board
    Comp: $404.88k
  • Dr. François Romagné Ph.D. (Age 60)
    Founder
  • Mr. Eric Vivier D.V.M. (Age 60)
    M.B.A., Ph.D., Founder, Senior VP & Chief Scientific Officer
  • Dr. Marc Bonneville Ph.D. (Age 64)
    Founder
  • Mr. Jean Jacques Fournié Ph.D.
    Founder
  • Mr. Alessandro Moretta M.D.
    Ph.D., Founder
  • Mr. Frederic Lombard M.B.A. (Age 49)
    Senior VP & CFO
  • Dr. Sonia Quaratino M.D. (Age 62)
    Ph.D., Executive VP, Chief Medical Officer & Member of Executive Board
  • Mr. Arvind Sood
    Executive VP, President of US Operations & Member of Executive Board

IPHYF Stock Analysis - Frequently Asked Questions

How have IPHYF shares performed in 2024?

Innate Pharma's stock was trading at $2.84 on January 1st, 2024. Since then, IPHYF stock has decreased by 9.2% and is now trading at $2.58.
View the best growth stocks for 2024 here
.

How do I buy shares of Innate Pharma?

Shares of IPHYF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:IPHYF) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners